🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interesting read. science.org/doi/10.1126/sc…

Excited to present my abstracts at #ACG2024 in Philadelphia, PA! Can't wait to share my research and connect with colleagues and mentors. #GITwitter #MedTwitter

Tremendous gratitude to all speakers and attendees at YCARE 2024! Your presence and participation helped make the event a success! NIAAA News Yale Digestive Diseases Yale Program in Addiction Medicine Yale School of Medicine Yale Internal Medicine Yale School of Public Health Yale Psychiatry Loren Laine Wajahat Mehal

Excellent talk by Basile Njei MD PhD MPH on cardiovascular risk stratification in MASLD using FibroX model #DDW2025

The great thing about #DDW is the unexpected encounters. I ran out of an #SSAT2025 session straight into a pack of GI doctors and the “meddies” let this surgeon survive 🙏 👏 Digestive Disease Week #DDW2025 SSAT American Gastroenterological Association (AGA) AASLD ASGE GI Endoscopy

Black and Hispanic patients were less likely to receive GLP-1 prescription therapy 💉 soon after a Type 2 diabetes or obesity diagnosis compared to Asian and white patients, according to new research from Sarpong Boateng, Basile Njei, MD, MPH, PhD, & team Yale New Haven Hosp @yaledigestive. #DDW2025 AASLD

Interestingly, among patients with fatty liver disease (MASLD), Asian individuals were the most likely to start GLP-1s early. This surprising trend shows how access and prescribing patterns can differ even within subgroups. #MASLD #DDW2025 AASLD

Honored to contribute to this important work! The FibroX model offers a novel, non-invasive approach to cardiovascular risk stratification in MASLD. Great presentation by Basile Njei, MD, MPH, PhD at #DDW2025 @Yaledigestive Yale New Haven Health